Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International Harmonization Should Focus On Post-Marketing Activities - HRG

This article was originally published in The Tan Sheet

Executive Summary

International harmonization efforts should include an emphasis on post-marketing activities, Public Citizen's Health Research Group Deputy Director Peter Lurie, MD, commented at an FDA public meeting on the future of the International Conference on Harmonization May 16.

You may also be interested in...



EU Evaluation Of FDA District Offices Under MRA To Begin By Feb. 2001

FDA expects European regulators to begin assessing agency district offices in the next six to eight months, Office of Regulatory Affairs Regional Director Deborah Ralston told a June 5 Food & Drug Law Institute meeting in Washington, D.C.

EU Evaluation Of FDA District Offices Under MRA To Begin By Feb. 2001

FDA expects European regulators to begin assessing agency district offices in the next six to eight months, Office of Regulatory Affairs Regional Director Deborah Ralston told a June 5 Food & Drug Law Institute meeting in Washington, D.C.

EU Evaluation Of FDA District Offices Under MRA To Begin By Feb. 2001

FDA expects European regulators to begin assessing agency district offices in the next six to eight months, Office of Regulatory Affairs Regional Director Deborah Ralston told a June 5 Food & Drug Law Institute meeting in Washington, D.C.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel